Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NAMPT | P43490 | 3/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426360 | 0.86 | SLC18A3 (0.58) | KMT2ASLC18A3ALDH1A1HPGDLMNA | |
| SCHEMBL520243 | 0.84 | ALDH1A1 (0.55) | KMT2ASLC18A3ALDH1A1HPGDLMNA | |
| SCHEMBL21814290 | 0.81 | KMT2A (0.53) | KMT2ANAMPTTDP1LMNAMAPT | |
| SCHEMBL520567 | 0.81 | NAMPT (0.55) | NAMPTSLC18A3 | |
| SCHEMBL4184580 | 0.81 | ALDH1A1 (0.58) | KMT2ASLC18A3ALDH1A1HPGDLMNA | |
| SCHEMBL7300130 | 0.81 | MAPT (0.55) | KMT2ATDP1ALDH1A1LMNAMAPT | |
| SCHEMBL25513439 | 0.80 | NAMPT (0.54) | KMT2ANAMPTALDH1A1LMNAHSD11B1 | |
| SCHEMBL521306 | 0.80 | SIRT6 (0.65) | KMT2ATDP1ALDH1A1HPGDLMNA | |
| SCHEMBL853823 | 0.79 | SLC18A3 (0.58) | KMT2ASLC18A3TDP1ALDH1A1HPGD | |
| SCHEMBL7529885 | 0.79 | SMN1; SMN2 (0.52) | KMT2ASLC18A3ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | KMT2A 114/4885NAMPT 2842/4885SLC18A3 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.